Enliven Therapeutics Inc. (ELVN)
$23.00 -$1.48 (-6.15%) 4:38 PM 12/12/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$1.24B -
Day's Range
$22.57 - $24.49 -
Volume
172,005 -
52 Week Low / High
$9.80 - $30.03 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
ELVN's Dividend
Hypothetical 10k Investment Jan 1, 2020
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
Analyists Ranking
- 6
- Strong Buy
- 1
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong Sell
- $31.00
- Target Price
Company News
-
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst — Sep 9th, 2024
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst HC Wainwright initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) and noted the company as an emerging biotech company developing next-gen precision-oriented small mol...
|
Portfolio
$5,000/year
Goal: $10,000/year
Comprised of 1 portfolios
$